JP2020200308A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020200308A5 JP2020200308A5 JP2020087116A JP2020087116A JP2020200308A5 JP 2020200308 A5 JP2020200308 A5 JP 2020200308A5 JP 2020087116 A JP2020087116 A JP 2020087116A JP 2020087116 A JP2020087116 A JP 2020087116A JP 2020200308 A5 JP2020200308 A5 JP 2020200308A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- piperidin
- carboxylic acid
- benzodioxol
- benzimidazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962850133P | 2019-05-20 | 2019-05-20 | |
| US62/850,133 | 2019-05-20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020200308A JP2020200308A (ja) | 2020-12-17 |
| JP2020200308A5 true JP2020200308A5 (enExample) | 2023-03-23 |
| JP7672201B2 JP7672201B2 (ja) | 2025-05-07 |
Family
ID=70775453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020087116A Active JP7672201B2 (ja) | 2019-05-20 | 2020-05-19 | Ｎａｓｈ／ｎａｆｌｄおよび関連疾患治療のための組合せ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220387402A1 (enExample) |
| EP (2) | EP4578460A3 (enExample) |
| JP (1) | JP7672201B2 (enExample) |
| CN (1) | CN113874019A (enExample) |
| AR (1) | AR118965A1 (enExample) |
| CA (1) | CA3140972C (enExample) |
| ES (1) | ES3039586T3 (enExample) |
| TW (1) | TW202110446A (enExample) |
| WO (1) | WO2020234726A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US12279989B2 (en) | 2011-02-04 | 2025-04-22 | Seed Health, Inc. | Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US12257272B2 (en) | 2015-12-24 | 2025-03-25 | Seed Health, Inc. | Method and system for reducing the likelihood of developing depression in an individual |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US12246043B2 (en) | 2013-12-20 | 2025-03-11 | Seed Health, Inc. | Topical application to treat acne vulgaris |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US12329783B2 (en) | 2013-12-20 | 2025-06-17 | Seed Health, Inc. | Method and system to improve the health of a person's skin microbiome |
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| WO2021104022A1 (zh) * | 2019-11-29 | 2021-06-03 | 广东东阳光药业有限公司 | Tropifexor的新晶型及其制备方法 |
| WO2021104021A1 (zh) * | 2019-11-29 | 2021-06-03 | 广东东阳光药业有限公司 | Tropifexor的新晶型及其制备方法 |
| TWI809334B (zh) * | 2019-12-10 | 2023-07-21 | 美商輝瑞股份有限公司 | ２－（（４－（（Ｓ）－２－（５－氯吡啶－２－基）－２－甲基苯并〔ｄ〕〔１，３〕二氧呃－４－基）哌啶－１－基）甲基）－１－（（（Ｓ）－氧呾－２－基）甲基）－１Ｈ－苯并〔ｄ〕咪唑－６－羧酸１，３－二羥基－２－（羥基甲基）丙烷－２－胺鹽之固體形式 |
| FI4097099T3 (fi) | 2020-02-07 | 2024-07-30 | Gasherbrum Bio Inc | Heterosyklisiä glp-1-agonisteja |
| GB202001856D0 (en) * | 2020-02-11 | 2020-03-25 | Inorbit Therapeutics Ab | Compounds useful in inhibiting ketohexokinase and methods of making and using the same |
| JP2021134211A (ja) * | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| JP2022058085A (ja) * | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| CR20230066A (es) | 2020-08-06 | 2023-05-29 | Gasherbrum Bio Inc | Agonistas del glp-1 heterocíclicos |
| JP2023538949A (ja) * | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| US20230089073A1 (en) | 2021-01-28 | 2023-03-23 | Carmot Therapeutics, Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| CN117222631A (zh) * | 2021-03-24 | 2023-12-12 | 诚益生物(美国)公司 | 苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-苯基-、苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-杂芳基-或苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-哌啶基-甲基-氧杂环丁烷基甲基-1h-苯并[d]咪唑-甲酸衍生物及其使用方法 |
| WO2022219495A1 (en) * | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| CA3215916A1 (en) * | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| JP2024516291A (ja) * | 2021-05-03 | 2024-04-12 | カーモット セラピューティクス インコーポレイテッド | ベンゾイミダゾイルｇｌｐ－１受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法 |
| WO2023025201A1 (zh) * | 2021-08-24 | 2023-03-02 | 南京明德新药研发有限公司 | 咪唑并环类化合物及其应用 |
| KR20240054335A (ko) * | 2021-08-31 | 2024-04-25 | 화이자 인코포레이티드 | 2-[(4-｛6-[(4-시아노-2-플루오로벤질)옥시]피리딘-2-일｝피페리딘-1-일)메틸]-1-[(2s)-옥세탄-2-일메틸]-1h-벤즈이미다졸-6-카르복실산,1,3-디히드록시-2-(히드록시메틸)프로판-2-아민 염의 고체 형태 |
| CN118948849A (zh) | 2021-09-08 | 2024-11-15 | 盐野义制药株式会社 | 用于预防和治疗与抗肥胖作用有关的疾病的药物 |
| US20250115612A1 (en) | 2021-10-05 | 2025-04-10 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators |
| US20240417393A1 (en) | 2021-10-05 | 2024-12-19 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| EP4476212A1 (en) * | 2022-02-10 | 2024-12-18 | Novartis AG | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| EP4490155A1 (en) | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4508047A1 (en) | 2022-04-14 | 2025-02-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| WO2024228213A1 (en) * | 2023-05-03 | 2024-11-07 | Dr. Reddy's Laboratories Limited | Crystalline forms of danuglipron |
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025080818A1 (en) * | 2023-10-10 | 2025-04-17 | Sagimet Biosciences Inc. | Combinations of fasn inhibitors and glp-1 agonists for liver diseases |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| US4465850A (en) * | 1980-09-02 | 1984-08-14 | Merck & Co., Inc. | Treatment of brain injury due to gray matter edema with (indanyloxy) butanoic acids |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| JP2527107B2 (ja) | 1991-04-16 | 1996-08-21 | 日本新薬株式会社 | 固体分散体の製造方法 |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| IL140622A0 (en) | 1998-07-06 | 2002-02-10 | Bristol Myers Squibb Co | Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof |
| US6488375B2 (en) | 1999-10-28 | 2002-12-03 | Ocular Sciences, Inc. | Tinted contact lens and method for making same |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| CA2439152C (en) | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
| US20040127504A1 (en) * | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| PT1753748E (pt) | 2004-05-12 | 2009-08-28 | Pfizer Prod Inc | Derivados de prolina e a sua utilização como inibidores de dipeptidil peptidase iv |
| CA2568056A1 (en) | 2004-05-25 | 2005-12-08 | Pfizer Products Inc. | Tetraazabenzo[e]azulene derivatives and analogs thereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| ES2487967T3 (es) | 2006-04-20 | 2014-08-25 | Pfizer Products Inc. | Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa |
| CN101541809A (zh) | 2006-11-29 | 2009-09-23 | 辉瑞产品公司 | 螺环酮乙酰基-CoA羧化酶抑制剂 |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| CA2724603A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| CA2724774C (en) | 2008-05-28 | 2013-06-25 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| EP2318370A1 (en) | 2008-07-29 | 2011-05-11 | Pfizer Inc. | Fluorinated heteroaryls |
| CN102149717B (zh) | 2008-08-28 | 2014-05-14 | 辉瑞大药厂 | 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物 |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| WO2010103438A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| AU2010222589B2 (en) | 2009-03-11 | 2012-08-16 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| JP2012520868A (ja) | 2009-03-20 | 2012-09-10 | ファイザー・インク | ３−オキサ−７−アザビシクロ［３．３．１］ノナン |
| CN102378574B (zh) * | 2009-03-30 | 2013-11-20 | 转化技术制药公司 | 取代的偶氮蒽衍生物、药物组合物及其使用方法 |
| JP2012526096A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Ｇｐｒ１１９調節因子 |
| WO2010128425A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
| JP2012528847A (ja) | 2009-06-05 | 2012-11-15 | ファイザー・インク | Ｇｐｒ１１９調節因子としてのｌ−（ピペリジン−４−イル）−ピラゾール誘導体 |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
| SG185515A1 (en) * | 2010-05-13 | 2012-12-28 | Amgen Inc | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| PT2621493T (pt) * | 2010-09-30 | 2016-11-14 | Pfizer | Inibidores de n1-pirazolospirocetona acetil-coa carboxilase |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP3397631B1 (en) | 2015-12-29 | 2021-04-07 | Pfizer Inc | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| CN106271089B (zh) | 2016-09-30 | 2019-01-25 | 英诺激光科技股份有限公司 | 一种激光薄膜刻蚀装置及方法 |
| AU2017374860B2 (en) * | 2016-12-16 | 2021-09-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| IL274820B2 (en) * | 2017-11-21 | 2024-11-01 | Pfizer | Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid |
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| JP7348179B2 (ja) | 2018-07-05 | 2023-09-20 | 株式会社Ｎｔｔドコモ | 端末、無線通信方法、基地局及びシステム |
-
2020
- 2020-05-15 CA CA3140972A patent/CA3140972C/en active Active
- 2020-05-15 EP EP25168997.2A patent/EP4578460A3/en active Pending
- 2020-05-15 US US17/612,672 patent/US20220387402A1/en active Pending
- 2020-05-15 ES ES20726962T patent/ES3039586T3/es active Active
- 2020-05-15 EP EP20726962.2A patent/EP3972596B1/en active Active
- 2020-05-15 CN CN202080037376.3A patent/CN113874019A/zh active Pending
- 2020-05-15 WO PCT/IB2020/054637 patent/WO2020234726A1/en not_active Ceased
- 2020-05-19 TW TW109116550A patent/TW202110446A/zh unknown
- 2020-05-19 JP JP2020087116A patent/JP7672201B2/ja active Active
- 2020-05-20 AR ARP200101424A patent/AR118965A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020200308A5 (enExample) | ||
| JP2019524831A5 (enExample) | ||
| US11780821B2 (en) | Inhibitors of fibroblast activation protein | |
| JP6435323B2 (ja) | 炎症性障害の治療のための新規化合物及びその医薬組成物 | |
| JP6454448B2 (ja) | ４−アミノ−２−（１Ｈ−ピラゾロ［３，４−ｂ］ピリジン−３−イル）−６−オキソ−６，７−ジヒドロ−５Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体及び心血管疾患を治療するためのｃＧＭＰモジュレーターとしてのそれぞれの（１Ｈ−インダゾール−３−イル）誘導体 | |
| TWI622589B (zh) | 細胞凋亡訊息調節激酶抑制劑 | |
| HRP20201748T1 (hr) | Inhibitori diacilglicerol-aciltransferaze | |
| JP6339595B2 (ja) | 炎症性障害の治療のための化合物及びその医薬組成物 | |
| KR101260162B1 (ko) | 당뇨병의 치료 또는 예방을 위한 디펩티딜 펩티다제-ⅳ 저해제로서의 아미노테트라히드로피란 | |
| US20180256573A1 (en) | Trk-INHIBITING COMPOUND | |
| TW201720820A (zh) | B型肝炎核心蛋白質調節劑 | |
| WO2008044700A1 (en) | GSK-3β INHIBITOR | |
| US20200216417A1 (en) | Inhibitors of fibroblast activation protein | |
| TW201629041A (zh) | 新穎化合物及其用於治療發炎病症及骨關節炎之醫藥組合物 | |
| AU2014283879B2 (en) | Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition thereof, preparation method and use thereof | |
| TWI803600B (zh) | 新穎的三唑酮衍生物或其鹽及包含彼等之醫藥組合物 | |
| JP6285873B2 (ja) | グリコーゲンシンターゼキナーゼ３ベータ阻害剤としての１ｈ−インダゾール−３−カルボキサミド化合物の使用 | |
| JPWO2020044266A5 (enExample) | ||
| TWI861497B (zh) | 作為cGAS抑制劑之具有C-連接環狀取代基之吡啶衍生物 | |
| TW202102474A (zh) | 吡咯化合物 | |
| KR20190085035A (ko) | 디아실글리세리드 o-아실트랜스퍼라제 2의 억제제로서 유용한 인돌 유도체 | |
| JP2020502058A (ja) | ジアシルグリセリドｏ−アシルトランスフェラーゼ２の阻害薬として有用なインダゾール誘導体 | |
| JP6404944B2 (ja) | ホスファチジルイノシトール３−キナーゼ阻害薬としてのピラジン誘導体 | |
| US20180291017A1 (en) | Aryl acylsulfonamides as blt1 antagonists | |
| CN102775385A (zh) | N-取代苯基-n’-取代杂环脲类化合物及其作为抗癌药物的应用 |